CoCites: A citation-based method for searching scientific literature

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

M A Nauck, M M Heimesaat, C Orskov, J J Holst, R Ebert, W Creutzfeldt. J Clin Invest 1993
Times Cited: 1228

Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.

Alice E Adriaenssens, Emma K Biggs, Tamana Darwish, John Tadross, Tanmay Sukthankar, Milind Girish, Joseph Polex-Wolf, Brain Y Lam, Ilona Zvetkova, Warren Pan, Davide Chiarugi, Giles S H Yeo, Clemence Blouet, Fiona M Gribble, Frank Reimann. Cell Metab 2019
Times Cited: 73

List of shared articles

Times cited

Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?
Tito Borner, Ian C Tinsley, Robert P Doyle, Matthew R Hayes, Bart C De Jonghe. Br J Pharmacol 2022

Anti-obesity drug discovery: advances and challenges.
Timo D Müller, Matthias Blüher, Matthias H Tschöp, Richard D DiMarchi. Nat Rev Drug Discov 2022

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
Qiming Tan, Seun E Akindehin, Camila E Orsso, Richelle C Waldner, Richard D DiMarchi, Timo D Müller, Andrea M Haqq. Front Endocrinol (Lausanne) 2022

Targeting the Enteroendocrine System for Treatment of Obesity.
Emily L Miedzybrodzka, Fiona M Gribble, Frank Reimann. Handb Exp Pharmacol 2022

Regulation of feeding and therapeutic application of bioactive peptides.
Hiroaki Ueno, Weidong Zhang, Masamitsu Nakazato. Pharmacol Ther 2022

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Laurie L Baggio, Daniel J Drucker. Mol Metab 2021

Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
Jonathan E Campbell. Mol Metab 2021

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
Qian Zhang, Challa Tenagne Delessa, Robert Augustin, Mostafa Bakhti, Gustav Colldén, Daniel J Drucker, Annette Feuchtinger, Cristina Garcia Caceres, Gerald Grandl, Alexandra Harger,[...]. Cell Metab 2021

Novel approaches to pharmacological management of type 2 diabetes in Japan.
Shizuka Kaneko. Expert Opin Pharmacother 2021

Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture.
Jens Juul Holst. Diabetes 2021

Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective.
Joanna Michałowska, Ewa Miller-Kasprzak, Paweł Bogdański. Nutrients 2021

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Julio Rosenstock, Carol Wysham, Juan P Frías, Shizuka Kaneko, Clare J Lee, Laura Fernández Landó, Huzhang Mao, Xuewei Cui, Chrisanthi A Karanikas, Vivian T Thieu. Lancet 2021

The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Michael A Nauck, Daniel R Quast, Jakob Wefers, Andreas F H Pfeiffer. Diabetes Obes Metab 2021

GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review.
Yusaku Mori, Takanori Matsui, Tsutomu Hirano, Sho-Ichi Yamagishi. Int J Mol Sci 2020

Leveraging the Gut to Treat Metabolic Disease.
Ruth E Gimeno, Daniel A Briere, Randy J Seeley. Cell Metab 2020

Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
Juan P Frías. Expert Rev Endocrinol Metab 2020